Clinical Trial Update: Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older [Phase 1]

View source ↗

Summary

This clinical trial update describes adding ruxolitinib to a dasatinib plus dexamethasone induction regimen for newly diagnosed Philadelphia chromosome-positive…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• DASATINIB (Dasatinib)
• DEXAMETHASONE (Dexamethasone)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Lymphoblastic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING